June 17, 2002
Avoiding insulin injections would greatly improve quality of life for many diabetics, and new products presented on June 15 and 16 at the American Diabetic Association annual meeting promise to do exactly that.
These include insulin in transdermal, oral pills, oral spray, and pulmonary inhaled forms. “Studies are underway to develop a convenient 24-hour insulin patch to provide painless, needle-free, basal insulin delivery for people with diabetes,” write Alan M. Smith and colleagues. “Basal insulin infusion has been achieved using a transdermal patch containing an unmodified approved insulin formulation without the use of chemical enhancers, iontophoresis or ultrasound.”
In this pharmacokinetic study, 5 nondiabetic volunteers tested an insulin patch delivery system containing a commercially available insulin lispro formulation in a liquid reservoir patch, creating shallow microscopic pores through the stratum corneum of the volar forearm. Serum lispro levels showed a steady infusion throughout the 12-hour patch application, with decline to baseline in approximately 2 hours. On average, serum insulin lispro levels were maintained above 5 mcU/mL between 1 and 12 hours.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!